Drugs / NEXI-002 T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04505813 | Aug 2020 → Nov 2024 | refractory plasma cell neoplasm | NexImmune Inc. | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEXI-002 T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04505813 ↗ |
| Modality | Cell therapy | “The NEXI-002 is an adoptive cellular therapy product which contains populations of antigen-specific CD8+ T cells.” NCT04505813 ↗ |